Lijst publicaties

Landolfo C, Achten ETL, Ceusters J, Baert T, Froyman W, Heremans R, Vanderstichele A, Thirion G, Van Hoylandt A, Claes S, Oosterlynck J, Van Rompuy AS, Schols D, Billen J, Van Calster B, Bourne T, Van Gorp T, Vergote I, Timmerman D, Coosemans A. Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors. Gynecol Oncol. 2020 Sep 26:S0090-8258(20)33918-4. doi: 10.1016/j.ygyno.2020.09.025.

Vankerckhoven A, Wouters R, Mathivet T, Ceusters J, Baert T, Van Hoylandt A, Gerhardt H, Vergote I, Coosemans A. Opposite Macrophage Polarization in Different Subsets of Ovarian Cancer: Observation from a Pilot Study. Cells. 2020 Jan 27;9(2):305. doi: 10.3390/cells9020305.

Coosemans A, Baert T, D'Heygere V, Wouters R, De Laet L, Van Hoylandt A, Thirion G, Ceusters J, Laenen A, Vandecaveye V, Vergote I. Increased Immunosuppression Is Related to Increased Amounts of Ascites and Inferior Prognosis in Ovarian Cancer. Anticancer Res. 2019 Nov;39(11):5953-5962. doi: 10.21873/anticanres.13800.

Coosemans A, Baert T, Ceusters J, Busschaert P, Landolfo C, Verschuere T, Van Rompuy AS, Vanderstichele A, Froyman W, Neven P, Van Calster B, Vergote I, Timmerman D. Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumors. Int J Gynecol Cancer. 2019 Nov;29(9):1381-1388. doi: 10.1136/ijgc-2019-000521.

Sprooten J, Ceusters J, Coosemans A, Agostinis P, De Vleeschouwer S, Zitvogel L, Kroemer G, Galluzzi L, Garg AD. Trial watch: dendritic cell vaccination for cancer immunotherapy. Oncoimmunology. 2019 Jul 18;8(11):e1638212. doi: 10.1080/2162402X.2019.1638212.

Baert T, Vankerckhoven A, Riva M, Van Hoylandt A, Thirion G, Holger G, Mathivet T, Vergote I, Coosemans A. Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer. Front Immunol. 2019 Jun 4;10:1273. doi: 10.3389/fimmu.2019.01273.

Coosemans A, Vankerckhoven A, Baert T, Boon L, Ruts H, Riva M, Blagden S, Delforge M, Concin N, Mirza MR, Ledermann JA, du Bois A, Vergote I. Combining conventional therapy with immunotherapy: A risky business? Eur J Cancer. 2019 May;113:41-44. doi: 10.1016/j.ejca.2019.02.014. Epub 2019 Apr 6.

Baert T, Van Camp J, Vanbrabant L, Busschaert P, Laenen A, Han S, Van Nieuwenhuysen E, Vergote I, Coosemans A. Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients. Gynecol Oncol. 2018 Jul;150(1):31-37. doi: 10.1016/j.ygyno.2018.05.004. Epub 2018 May 9.

Baert T, Garg AD, Agostinis P, Vergote I, Coosemans A. Orientation of Preclinical Research in Ovarian Cancer. Int J Gynecol Cancer. 2017 Oct;27(8):1579-1586. doi: 10.1097/IGC.0000000000001053.

Baert T, Vergote I, Coosemans A. Ovarian cancer and the immune system. Gynecol Oncol Rep. 2017 Jan 6;19:57-58. doi: 10.1016/j.gore.2017.01.002.

Baert T, Garg AD, Vindevogel E, VAN Hoylandt A, Verbist G, Agostinis P, Vergote I, Coosemans An. In Vitro Generation of Murine Dendritic Cells for Cancer Immunotherapy: An Optimized Protocol. Anticancer Res. 2016 Nov;36(11):5793-5801. doi: 10.21873/anticanres.11163.

Vindevogel E, Baert T, VAN Hoylandt A, Verbist G, Vande Velde G, Garg AD, Agostinis P, Vergote I, Coosemans An. The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian Cancer. Anticancer Res. 2016 Nov;36(11):5781-5792. doi: 10.21873/anticanres.11162.

Coosemans A, Tuyaerts S, Morias K, Corthals J, Heirman C, Thielemans K, Van Gool SW, Vergote I, Amant F. mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L, and CD70). Methods Mol Biol. 2016;1428:277-83. doi: 10.1007/978-1-4939-3625-0_18.

Coosemans A, Decoene J, Baert T, Laenen A, Kasran A, Verschuere T, Seys S, Vergote I. Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course. Oncoimmunology. 2015 Dec 21;5(4):e1111505. doi: 10.1080/2162402X.2015.1111505.

Baert T, Storme N, Van Nieuwenhuysen E, Uyttebroeck A, Van Damme N, Vergote I, Coosemans A. Ovarian cancer in children and adolescents: A rare disease that needs more attention. Maturitas. 2016 Jun;88:3-8. doi: 10.1016/j.maturitas.2016.03.003. Epub 2016 Mar 8.

Baert T, Verschuere T, Van Hoylandt A, Gijsbers R, Vergote I, Coosemans A. The dark side of ID8-Luc2: pitfalls for luciferase tagged murine models for ovarian cancer. J Immunother Cancer. 2015 Dec 15;3:57. doi: 10.1186/s40425-015-0102-0.

Coosemans A, Baert T, Vergote I. A view on dendritic cell immunotherapy in ovarian cancer: how far have we come? Facts Views Vis Obgyn. 2015;7(1):73-8.

Baert T, Timmerman D, Vergote I, Coosemans A. Immunological parameters as a new lead in the diagnosis of ovarian cancer. Facts Views Vis Obgyn. 2015;7(1):67-72.

Coosemans A, Vergote I, Van Gool SW. Dendritic cell-based immunotherapy in ovarian cancer. Oncoimmunology. 2013 Dec 1;2(12):e27059. doi: 10.4161/onci.27059. Epub 2013 Nov 6.